Abstract 5372
Background
Alzheimer’s disease showed different connections with various types of cancers and, even, both are protecting from each other. Some studies attributed it to shared genetic backgrounds. One of the shared mutations is located on APOE4 gene, a risk factor in Alzheimer’s, and was connected to chemotherapy-related deterioration of cognitive functions in breast cancer patients. Our aim is to examine the addon effect of radiation therapy on the risk of death from Alzheimer’s disease.
Methods
We collected data from 13 USA cancer registries enrolled in Surveillance Epidemiology and End Results program using SEER*stat software. We enrolled patients diagnosed with head and neck cancers or brain cancers between 1992 and 2016. The event was defined as death due to Alzheimer’s disease following the cancer diagnosis. Moreover, we have calculated Multiple Primary Standardized Incidence Ratios and excess risk per 10,000 person-years, to estimate the change of risk following the diagnosis when compared to the general population. Besides, we calculated the effect of gender, age, and receiving radiation for cancer.
Results
Out of 142,541 patients (59,630 patients with brain malignancies, and 82,911 with head and neck malignancies), 151 died due to Alzheimer’s after more than 10 years following a cancer diagnosis; 20 had brain malignancies, and 131 had other head and neck malignancies. The risk of Alzheimer’s death increased significantly after more than 10 years of a cancer diagnosis with an O/E ratio of 1.35 and an excess risk of 2.72 per 10,000. The risk increased significantly among females (81 females and O/E was 1.4) and males (70 and O/E was 1.29). Alzheimer’s was the cause of death in 52 patients who received Radiation therapy, and 13 patients who received chemotherapy with O/Es of 1.45 and 1.59 respectively. The risk of disease-related mortality was high in patients older than 70 years, while patients who were diagnosed with cancer earlier did not show a significant increase in their risk of Alzheimer’s death than the general population.
Conclusions
Risk of Alzehimer’s-related mortality increases significantly among survivors of head and neck cancers and brain cancers. Further studies shall address the biological risk-modifying effects of aging, gender, and treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4883 - A New Population Model Validated Pharmacokinetic Similarity of HLX01 and Rituximab in B-Cell Lymphoma
Presenter: Yuankai Shi
Session: Poster Display session 1
Resources:
Abstract
4908 - Efficacy of salvage therapy in the treatment of Helicobacter pylori-positive gastric low-grade mucosa-associated lymphoid tissue lymphoma
Presenter: Sung-Nam Lim
Session: Poster Display session 1
Resources:
Abstract
2360 - Mutational analysis of extranodal marginal zone lymphoma using next generation sequencing
Presenter: Seok Jae Huh
Session: Poster Display session 1
Resources:
Abstract
2430 - Clinical features, treatment and outcomes of colon and rectum mucosa-associated lymphoid tissue (MALT) lymphoma: Literature reviews published in English between 1993 and 2017
Presenter: Jeong Yeon Kim
Session: Poster Display session 1
Resources:
Abstract
4654 - Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 52 patients
Presenter: Guldane Cengiz Seval
Session: Poster Display session 1
Resources:
Abstract
1732 - Safety and efficacy of Bendamustine and Rituximab (BR) regimen in Indian Chronic Lymphocytic Leukemia patients
Presenter: Ajay Gogia
Session: Poster Display session 1
Resources:
Abstract
5784 - N-terminal B-type natriuretic peptide (NT-proBNP) as an independed prognostic marker for patients with newly diagnosed multiple myeloma complicated by dialysis-dependent renal failure
Presenter: Sergey Semochkin
Session: Poster Display session 1
Resources:
Abstract
836 - The first-line effect of Bortezomib-based Therapy on Clinical Outcomes for Taiwanese Patients with multiple myeloma
Presenter: Ching-Liang Ho
Session: Poster Display session 1
Resources:
Abstract
2085 - Impact of Donor Lymphocyte Infusion in Relapsing Myeloid Neoplasms Post Allogeneic Hematopoietic Stem Cell Transplantation
Presenter: Hanafy Hafez
Session: Poster Display session 1
Resources:
Abstract
6079 - Invasive fungal diseases in patients with Hodgkin’s lymphoma before and after allogeneic hematopoietic stem cell transplantation
Presenter: Marina Popova
Session: Poster Display session 1
Resources:
Abstract